Maravai LifeSciences Reports Q1 2025 Financial Results

Maravai Lifesciences Holdings, Inc. ( (MRVI) ) has released its Q1 earnings. Here is a breakdown of the information Maravai Lifesciences Holdings, Inc. presented to its investors.

Maravai LifeSciences Holdings, Inc. is a global provider of life science reagents and services, catering to researchers and biotech innovators, primarily in the fields of nucleic acid synthesis and biologics safety testing.

In its first quarter of 2025 financial results, Maravai reported a revenue of $46.9 million, which exceeded its guidance range, despite a net loss of $52.9 million. The company emphasized its commitment to a return-to-growth strategy amid a challenging macroeconomic environment.

The financial performance revealed a 27% year-over-year revenue decline, primarily due to a significant drop in nucleic acid production revenue, which fell by 37.5% due to reduced demand for high-volume CleanCap orders. However, the biologics safety testing segment remained stable. The adjusted EBITDA also reflected a loss of $10.5 million, compared to a positive $7.8 million in the previous year.

Looking ahead, Maravai maintains its full-year 2025 revenue guidance between $185 million and $205 million, focusing on its core business and strategic growth initiatives. The management remains optimistic about leveraging its differentiated technologies and customer focus to navigate the evolving market landscape and drive long-term value.